Table 2.
Characteristics of Patients With Concordant and Discordant Risk Group Assessment Based on SvO2 and Cardiac Index
| Variables | SvO2 Better Than Cardiac Index (n = 43) | Equal Risk Group (n = 77) | SvO2 Worse Than Cardiac Index (n = 38) | P Value (ANOVA/χ2)a |
|---|---|---|---|---|
| Age, y | 60 ± 16 | 56 ± 16 | 58 ± 18 | .66 |
| Female sex | 32 (74) | 59 (77) | 22 (58) | .26 |
| Race | .09 | |||
| White | 37 (86) | 67 (87) | 27 (71) | |
| Black | 5 (12) | 6 (8) | 11 (29) | |
| Others | 1 (2) | 4 (5) | 0 (0) | |
| BSA, m2 | 1.9 ± 0.3 | 1.9 ± 0.3 | 1.9 ± 0.3 | .98 |
| Type of PAH | ||||
| Idiopathic PAH | 38 (88) | 68 (88) | 37 (97) | .38 |
| SpO2, % | 94 ± 5 | 95 ± 3 | 93 ± 5 | .34 |
| Oxygen supplementation at rest (yes) | 18 (43) | 23 (32) | 12 (34) | .64 |
| WHO functional class | 2.8 ± 0.7 | 2.7 ± 0.8 | 2.9 ± 0.9 | .79 |
| 6MWD, m (n = 153) | 312 ± 127 | 324 ± 113 | 235 ± 99 | .007 |
| Dlco % predicted (n = 141) | 57 ± 27 | 63 ± 23 | 49 ± 18 | .07 |
| NT-pro BNP, pg/mL (n = 76) | 1,481 ± 1,756 | 1,602 ± 3,771 | 2,999 ± 2,391 | .35 |
| Hemoglobin, g/dL | 14.4 ± 2.2 | 13.7 ± 1.9 | 12.9 ± 2.3 | .03 |
| Carboxyhemoglobin, % (n = 80) | 1.2 ± 0.3 | 1.4 ± 0.7 | 1.4 ± 0.7 | .39 |
| Methemoglobin, % (n = 79) | 0.9 ± 0.4 | 1.0 ± 0.5 | 0.9 ± 0.5 | .66 |
| Echocardiography | ||||
| RV function (moderate/severe) | 26 (62) | 45 (63) | 22 (65) | .97 |
| RVSP, mm Hgb | 76 ± 25 | 75 ± 22 | 84 ± 25 | .35 |
| Pericardial effusion (mild or more) | 4 (10) | 14 (19) | 6 (16) | .59 |
| PFOc | 13 (30) | 14 (18) | 12 (32) | .15 |
| Intrapulmonary shuntc | 2 (4.7) | 0 (0) | 3 (8) | |
| RHC | ||||
| Heart rate, beats/min | 78 ± 17 | 80 ± 13 | 81 ± 16 | .69 |
| RAP, mm Hg | 8 ± 5 | 10 ± 7 | 11 ± 5 | .37 |
| mPAP, mm Hg | 47 ± 12 | 52 ± 13 | 53 ± 11 | .20 |
| PAWP, mm Hg | 9 ± 3 | 10 ± 3 | 10 ± 3 | .40 |
| CO, L/min | 3.8 ± 0.7 | 4.6 ± 1.6 | 4.9 ± 0.9 | < .001 |
| Cardiac index, L/min/m2 | 2.0 ± 0.3 | 2.4 ± 0.7 | 2.6 ± 0.3 | < .001 |
| SvO2, % | 67 ± 4 | 63 ± 10 | 57 ± 6 | < .001 |
| PVR, Wood units | 11 ± 4 | 10 ± 5 | 9 ± 3 | .49 |
Values are mean ± SD, No. (%), or as otherwise indicated. Data on 6MWD, NT-pro BNP, DLCO, carboxyhemoglobin, and methemoglobin were only available in the number of patients indicated in parenthesis. Variables without associated number were obtained in all subjects. ANOVA = analysis of variance; PFO = patent foramen oval. See Table 1 legend for expansion of other abbreviations.
a
P value adjusted by false discovery rate correction for multiple comparisons using Benjamini and Hochberg methodology.
b
In 11 patients, the RVSP could not be adequately measured and is therefore not reported.
c
Bubble study was not done in one patient.